US20060257324A1 - Pharmaceutical solution formulations for pressurised metered dose inhalers - Google Patents

Pharmaceutical solution formulations for pressurised metered dose inhalers Download PDF

Info

Publication number
US20060257324A1
US20060257324A1 US11/408,026 US40802606A US2006257324A1 US 20060257324 A1 US20060257324 A1 US 20060257324A1 US 40802606 A US40802606 A US 40802606A US 2006257324 A1 US2006257324 A1 US 2006257324A1
Authority
US
United States
Prior art keywords
inhaler
drug substances
hfa
active drug
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/408,026
Inventor
David Lewis
Brian Meakin
Gaetano Brambilla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38230023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060257324(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2000/004635 external-priority patent/WO2001089480A1/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to US11/408,026 priority Critical patent/US20060257324A1/en
Assigned to CHIESI FARMACEUTICI S.P.A. reassignment CHIESI FARMACEUTICI S.P.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BRAMBILLA, GAETANO, LEWIS, DAVID ANDREW, MEAKIN, BRIAN JOHN
Publication of US20060257324A1 publication Critical patent/US20060257324A1/en
Priority to MEP-2016-22A priority patent/ME02342B/en
Priority to PL07724357T priority patent/PL2010190T3/en
Priority to KR1020087018846A priority patent/KR101311662B1/en
Priority to PT77243574T priority patent/PT2010190E/en
Priority to MX2008013460A priority patent/MX2008013460A/en
Priority to CA2649556A priority patent/CA2649556C/en
Priority to BRPI0709510-4A priority patent/BRPI0709510A2/en
Priority to CNA2007800069518A priority patent/CN101389341A/en
Priority to EP07724357.4A priority patent/EP2010190B1/en
Priority to PCT/EP2007/003420 priority patent/WO2007121913A2/en
Priority to JP2009505773A priority patent/JP5289306B2/en
Priority to CN201610483860.4A priority patent/CN106074359A/en
Priority to CN201610428382.7A priority patent/CN105963249A/en
Priority to EA200802012A priority patent/EA016262B1/en
Priority to CN2012103537724A priority patent/CN102908308A/en
Priority to ES07724357T priority patent/ES2424753T3/en
Priority to AU2007241336A priority patent/AU2007241336C1/en
Priority to DK07724357.4T priority patent/DK2010190T3/en
Priority to RS20130386A priority patent/RS52940B/en
Priority to SI200731304T priority patent/SI2010190T1/en
Priority to ZA2008/08965A priority patent/ZA200808965B/en
Priority to US12/255,075 priority patent/US20090130026A1/en
Priority to CY20131100703T priority patent/CY1114215T1/en
Priority to HRP20130835TT priority patent/HRP20130835T1/en
Priority to US15/353,978 priority patent/US10525006B2/en
Priority to US16/689,611 priority patent/US11213485B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to pharmaceutical solution to be used with pressurised metered dose inhalers (pMDIs) suitable for aerosol administration.
  • the invention relates to aerosol solution formulations to be used with pressurised metered dose inhalers (pMDIs), suitable for the administration of a medicament to the lungs, said medicament comprising two or more active drug substances.
  • the invention relates to a method for delivering two or more active drug substances to the lungs by inhalation from a single inhaler.
  • one of the drug substances is a long-acting ⁇ 2 -agonist.
  • Treatment of pulmonary disease with inhaled aerosol drugs offers advantages over systemic therapy, including a more rapid onset and reduced adverse effects, because of direct targeting of the lungs.
  • MDIs Pressurised metered dose inhalers
  • MDI uses a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol.
  • Formulations for aerosol administration via MDIs can be solutions or suspensions.
  • Solution formulations offer the advantage of being homogeneous with the active ingredient and excipients completely dissolved in the propellant vehicle or its mixture with suitable co-solvents such as ethanol. Solution formulations also obviate physical stability problems associated with suspension formulations so assuring more consistent uniform dosage administration.
  • the preferred propellants used in aerosols for pharmaceutical use have been a group of chlorofluorocarbons which are commonly called Freons or CFCs, such as CCl 3 F (Freon 11 or CFC-11), CCl 2 F 2 (Freon 12 or CFC-12), and CClF 2 -CClF 2 (Freon 114 or CFC-114).
  • Freons or CFCs such as CCl 3 F (Freon 11 or CFC-11), CCl 2 F 2 (Freon 12 or CFC-12), and CClF 2 -CClF 2 (Freon 114 or CFC-114).
  • CFC chlorofluorocarbon
  • Hydrofluoroalkanes (HFAs) known also as hydro-fluoro-carbons (HFCs)] contain no chlorine and are considered less destructive to ozone and these are proposed as substitutes for CFCs.
  • HFAs and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of medicinal aerosol formulations using such HFA propellant systems have been disclosed.
  • Drugs commonly delivered by inhalation include short-acting and long-acting ⁇ 2 -agonists, anticholinergics/antimuscarinic agents, and corticosteroids.
  • ⁇ 2 -Adrenoceptor agonists and antimuscarinic agents are the most effective bronchodilators, whereas corticosteroids are the most effective controllers of the underlying inflammatory process in the airways.
  • Examples of long-acting bronchodilator ⁇ 2 -agonists belonging to the class of the phenylalkylamino derivatives are formoterol, salmeterol and 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone (also referred to as carmoterol).
  • Asthma and chronic obstructive pulmonary disease (COPD) are the most common broncho-pulmonary diseases and represent a major public health problem.
  • Asthma is a disease characterized by airway inflammation and smooth muscle dysfunction. Therefore to achieve optimum asthma control, therapy should be targeted against these underlying components.
  • LAA long-acting inhaled ⁇ 2 -agonist
  • ICS inhaled corticosteroid
  • Bronchodilator therapy is the first step treatment in patients with COPD, but current guidelines recommend the addition of inhaled corticosteroids to bronchodilators.
  • anticholinergics and beta-agonists As far as anticholinergics and beta-agonists are concerned, they reduce bronchoconstriction through different mechanism, and there is a long history of combination therapy in the past with short-acting agents in these classes for chronic obstructive pulmonary disease. More effective drug combinations may allow lower doses and thereby improve safety.
  • a method and formulations in the form of HFA solution to be administered by MDI's aimed at providing pharmaceutical doses of two or more bronchodilating and/or anti-inflammatory compounds to the lung and especially a ⁇ 2 -agonist in combination with at least a further active compound for a more efficacious treatment of broncho-pulmonary diseases, in particular asthma and COPD.
  • FIG. 1 shows the titration curve normalised to the usual fill volume of a pMDI can (12 ml) resulting from Example 1(a);
  • FIG. 2 shows the pH profile for the titration experiment reported in Example 1(b);
  • FIG. 3 shows the cumulative % undersize BDP and FF mass distributions for the sample as determined in Example 6.
  • a pharmaceutical composition comprising two or more active substances and in particular a long acting ⁇ 2 -agonist belonging to the class of phenylalkylamino derivatives in solution in a liquefied HFA propellant and a co-solvent selected from pharmaceutically acceptable alcohols.
  • Active ingredients which may be used in the aerosol compositions of the invention are short- and long-acting ⁇ 2 -adrenergic agonists, preferably long-acting ⁇ 2 -adrenergic agonists such as formoterol, salmeterol, carmoterol and salts thereof and their combinations with other active ingredients, preferably selected from the group of corticosteroids or anticholinergic atropine-like derivatives, antimuscarinic M3 inhibitors or phosphodiesterase 4 (PDE4) inhibitors.
  • ⁇ 2 -adrenergic agonists preferably long-acting ⁇ 2 -adrenergic agonists such as formoterol, salmeterol, carmoterol and salts thereof and their combinations with other active ingredients, preferably selected from the group of corticosteroids or anticholinergic atropine-like derivatives, antimuscarinic M3 inhibitors or phosphodiesterase 4 (PDE4) inhibitors.
  • PDE4 phosphodiesterase 4
  • Preferred corticosteroids are beclomethasone dipropionate, budesonide and its 22R-epimer, rofleponide, ciclesonide, fluticasone propionate, mometasone furoate or triamcinolone and its ester such as triamcinolone acetonide.
  • Preferred anticholinergic atropine-like derivatives are ipratropium bromide, oxitropium bromide, tiotropium bromide or glycopyrronium bromide.
  • Preferred long acting ⁇ 2-agonists are formoterol, carmoterol and salmeterol and salts thereof.
  • the first active ingredient is a long acting ⁇ 2-agonists belonging to the formula sketched below wherein R is 1-formylamino-2-hydroxy-phen-5-yl (formoterol) or 8-hydroxy-2(1H)-quinolinon-5-yl (TA 2005) or one of their salts, solvates, solvates of the salts or stereoisomers.
  • R is 1-formylamino-2-hydroxy-phen-5-yl (formoterol) or 8-hydroxy-2(1H)-quinolinon-5-yl (TA 2005) or one of their salts, solvates, solvates of the salts or stereoisomers.
  • the formulation be suitable for delivering a therapeutic amount of the active ingredient in one or two actuations.
  • the formulation will be suitable for delivering 6 to 12 ⁇ g/dose of formoterol fumarate.
  • the formulation will be advantageously suitable for delivering 0.5 to 8 ⁇ g/dose, preferably 1 to 4 ⁇ g/dose, more preferably from 1 to 2 ⁇ g/dose of carmoterol hydrochloride (TA 2005).
  • dose it is meant the amount of active ingredient delivered by a single actuation of the inhaler.
  • the formulation of the invention may further contain small amounts of a mineral acid to adjust the apparent pH to between 2.5 and 5.0.
  • the formulations of the invention may be contained in a pressurized MDI having part of all of the internal metallic surfaces made of anodised aluminium, stainless steel or lined with an inert organic coating.
  • preferred coatings are epoxy-phenol resins, perfluoroalkoxyalkane, perfluoroalkoxyalkylene, perfluoroalkylenes such as polytetrafluoroethylene, fluorinated-ethylene-propylene, polyether sulfone and a mixture of fluorinated-ethylene-propylene and polyether sulfone.
  • Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
  • cans having a rolled-in rim and preferably a part or full rollover rim may be used.
  • the pharmaceutical composition may further contain a low volatility component, further improving the stability of the formulation.
  • a low volatility component with a reduced polarity with respect to the co-solvent such as an ester may allow either to reduce the amount of acid to be added for adjusting the pH and diminish the polarity of the medium so limiting the possible uptake of environmental water.
  • active ingredients such as formoterol, it is well known that the latter (e.g., humidity) could be detrimental to the stability of the active ingredient during storage.
  • a pressurised MDI for administering pharmaceutical doses consisting of a container filled with a pharmaceutical composition comprising a long-acting ⁇ 2 agonist selected from formoterol fumarate in solution in HFA 134a as a propellant in turn containing from 5% to 20%, preferably from 6% to 15% w/w ethanol as a co-solvent, the apparent pH of said solution having been adjusted to between 3.0 and 3.5 by addition of small amounts of hydrochloric acid.
  • % w/w means the weight percentage of the component in respect to the total weight of the composition.
  • a pressurised MDI filled with a pharmaceutical composition consisting of a solution comprising formoterol fumarate in combination with a corticosteroid in HFA 134a as a propellant in turn containing from 6% to 15% w/w, preferably 12% w/w ethanol as a co-solvent, the apparent pH of said solution having been adjusted to between 3.0 and 3.5 by addition of small amounts of hydrochloric acid.
  • the corticosteroid is beclometasone dipropionate.
  • a pressurised MDI consisting of a coated container filled with a pharmaceutical composition consisting of a solution of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxy-phenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride (TA 2005) in combination with a corticosteroid in HFA 134a as a propellant in turn containing from 6% to 15% w/w, preferably 12% w/w ethanol as a co-solvent, the apparent pH of said solution having been adjusted to between 3.0 and 5.0 by addition of small amounts of a mineral acid.
  • the corticosteroid is budesonide or an epimer thereof.
  • WO 97/47286 disclose HFA formulations in the form of suspensions in which ⁇ 2 -agonists such formoterol and salbutamol are either exemplified and/or claimed.
  • WO 99/65464 refers to HFA formulations containing two or more active ingredients in which at least one is in suspension.
  • the preferred formulations comprise salbutamol sulphate in suspension.
  • WO 98/34596 describes solution compositions for use in an aerosol inhaler, comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler.
  • HFA hydrofluoroalkane
  • MMAD mass median aerodynamic diameter
  • EP 673240 proposes the use of acids as stabilisers preventing the chemical degradation of the active ingredient in aerosol solution formulations comprising HFAs.
  • Most examples relate to ipratropium bromide, an anticholinergic drug and only an example is presented for a ⁇ 2 -agonist, i.e. fenoterol.
  • salbutamol is claimed, no exemplary formulations are provided.
  • the stability data are reported only for ipratropium and the patentee does not distinguish between the use of organic and inorganic acids.
  • no guidance is given with respect to the amount of acid which has to be added in order to stabilise the medicaments without compromising the stability of the whole composition in the can. The only hint can be found on page 5, lines 15 to 16 which says that an amount of inorganic acid should be added to obtain a pH value from 1 to 7, so a very broad and generic range.
  • WO 98/34596 refers to solution formulations containing a propellant and a physiologically acceptable polymer which could help the solubilisation and the stability as well of the active ingredients.
  • WO 00/06121 refers to propellant mixtures for aerosol dinitrogen monoxide and a hydrofluoroalkane in the preparation of suspension and solution aerosols.
  • the use of dinitrogen monoxide may improve the stability at storage of oxidation-sensitive active ingredients.
  • ⁇ 2 -agonist such as levosalbutamol sulphate, formoterol fumarate and salmeterol xinafoate, only examples referred to suspensions are reported.
  • Examples refer to solutions of formoterol fumarate containing an HFA propellant and ethanol as co-solvent, filled in conventional aluminium or plastic coated glass cans.
  • loss of 10% of active ingredient does not meet the criteria of acceptance.
  • following the teaching of WO 99/65460 stable formoterol solution formulations cannot be provided.
  • WO 03/074025 refers to a pharmaceutical aerosol formulation to be administered by pressurized metered dose inhalers which comprises as active ingredient a long acting ⁇ 2-agonist selected from a 2(1H)-quinolinone derivative, a stereoisomer, physiologically acceptable salt and solvate thereof, in a solution consisting of a liquefied HFA propellant, a co-solvent and optionally an amount of water up to 5% on the total weight of the formulation.
  • a long acting ⁇ 2-agonist selected from a 2(1H)-quinolinone derivative, a stereoisomer, physiologically acceptable salt and solvate thereof, in a solution consisting of a liquefied HFA propellant, a co-solvent and optionally an amount of water up to 5% on the total weight of the formulation.
  • the formulation is able to deliver, on actuation of the inhaler, a fraction of superfine particles equal to or less than 1.1 micron up to 50% or more so allowing the drug to reach the small peripheral airways region where it exercises its pharmacological effects.
  • WO 2004/075896 refers to a combined preparation comprising:
  • One of the preferred combination products comprises the hydrochloride salt CHF 4226 and a corticosteroid: it has indeed been found that, in such a combination, both the bronchodilator and the anti-inflammatory effects increase.
  • a filled device such as an aerosol inhaler
  • a composition of the invention comprising:
  • the formulation is actuated by a metering valve capable of delivering a volume of between 50 ⁇ l and 100 ⁇ l.
  • Metering valves fitted with gaskets made of chloroprene-based rubbers can preferably be used to reduce the ingress of moisture which, as previously mentioned, can adversely affect the stability of the drug during storage.
  • further protection can be achieved by packaging the product in a sealed aluminium pouch.
  • the hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof.
  • the co-solvent is usually an alcohol, preferably ethanol.
  • the low volatility component when present, has a vapour pressure at 25° C. lower than 0.1 kPa, preferably lower than 0.05 kPa.
  • it could be selected from the group of glycols, particularly propylene glycol, polyethylene glycol and glycerol or esters, for example ascorbyl palmitate, isopropyl myristate and tocopherol esters.
  • compositions of the present invention may contain from 0.1 to 10% w/w of said low volatility component, preferably between 0.3 to 5% w/w, more preferably between 0.4 and 2.0% w/w.
  • Propylene glycol, polyethylene glycol, glycerol with residual water less than 0.1% w/w and esters of long-chain fatty acids are the preferred low-volatility components. More preferred are those with a dipole moment less than 2.0 or with a dielectric static constant less than 20, preferably less than 10. Particularly preferred is isopropyl myristate.
  • the function of the low volatility component is to modulate the MMAD of the aerosol particles and optionally to further improve the stability of the formulation.
  • particularly preferred is the use of isopropyl myristate.
  • the apparent pH range is advantageously comprised between 2.5 and 5.0, preferably between 3.0 and 5.0.
  • Strong mineral acids such as hydrochloric, nitric, sulphuric or phosphoric are preferably used to adjust the apparent pH.
  • the amount of acid to be added to reach the desired apparent pH will be pre-determined in the model vehicle reported before.
  • an amount comprised between 3 and 3.5 ⁇ l of 1.0 M hydrochloric acid should be added to obtain an apparent pH between 3.0 and 3.5.
  • a recommended combination is the combination of an inhaled corticosteroid (ICS) and a long-acting ⁇ 2-agonist (LABA) bronchodilator in the treatment of persistent asthma, to provide both anti-inflammatory and bronchodilating effects.
  • ICS inhaled corticosteroid
  • LAA long-acting ⁇ 2-agonist
  • the size of the solid particles can be easily pre-determined by the micronization process.
  • Co-deposition in the same lung region could maximize the synergistic effects, but the two active ingredients have to show exactly the same distribution profile.
  • each liquid particle generated during the MDIs atomisation process contains drug concentrations consistent with the liquid properties of the product's solution formulation and that this consistency is maintained for the residual particles following excipient evaporation.
  • substantially all of the liquid particles emitted on actuation of the inhaler contain the two or more drug substances in a ratio which is substantially the same as the ratio of the two or more drug substances in the solution formulation contained in the inhaler.
  • the liquid droplets emitted on actuation of the inhaler contain the two or more drug substances in a ratio (when expressed as a ratio obtained by dividing the mass of the major component by the mass of the minor component) which preferably differs by less than 15%, preferably less than 10%, more preferably less than 5%, even more preferably less than 2%, even more preferably less than 1%, from the ratio of the two or more drug substances in the solution formulation contained in the inhaler.
  • the ratio of the two or more drug substances in the solution formulation will in part depend on the identity of the drug substances and the condition and subject being treated. However, in view of the teachings of the present specification, determination of such ratios is within the abilities of those skilled in the art.
  • the mass ratio of beclometasone to formoterol fumarate may preferably be 100:0.1 to 100:50, more preferably 100:1 to 100:20, even more preferably 100:2 to 100:10.
  • the mass ratio of budesonide to carmoterol hydrochloride may preferably be 100:0.01 to 100:15, more preferably 100:0.05 to 100:10, even more preferably 100:0.1 to 100:7, even more preferably 100:0.5 to 100:5, even more preferably 100:0.5 to 100:4, even more preferably 100:0.5 to 100:3.
  • each droplet of the aerosol cloud emitted on actuation of the inhaler containing a solution of different active drug substances dries to give particles of the active materials with identical size distributions in the correct ratio.
  • the liquid droplets dry to give particles of the two or more drug substances, and the particles of the two or more drug substances have substantially the same particle size distribution.
  • the fine particle fractions (at ⁇ 5 ⁇ m) of the two or more drug substances preferably differ by less than 15%, preferably less than 10%, more preferably less than 5%, even more preferably less than 2%, even more preferably less than 1%.
  • the fine particle fractions (at ⁇ 1 ⁇ m) of the two or more drug substances preferably differ by less than 15%, preferably less than 10%, more preferably less than 5%, even more preferably less than 2%, even more preferably less than 1%.
  • the spray cloud of finely divided liquid particles dispersed in a gas stream emitted from the MDI is a dynamic system quickly evaporating and moving through the air way from the actuator.
  • the invention is particularly directed to a method for delivering two or more active drug substances to the lung by inhalation from a single pressurized metered dose inhaler product, said inhaler containing a HFA/cosolvent based solution formulation wherein all the active drug substances are fully dissolved in the formulation.
  • PSD particle size distribution
  • FIG. 1 shows the resultant titration curve normalised to the usual fill volume of a pMDI can (12 ml).
  • Formoterol formulations (12 ⁇ g/100 ⁇ l) were prepared by dissolving 1.44 mg of formoterol fumarate in HFA 134a containing 12% w/w ethanol with and without 1.0% w/w isopropyl myristate. The latter was included as a non-volatile excipient with the potential for increasing MMAD if so desired. It also improves the solubility of formoterol in the vehicle and reduces polarity of the vehicle compared to the addition of glycerol.
  • pMDI cans containing 3.1 to 3.4 ⁇ l 1.0 M hydrochloric acid were set down on storage, upright and inverted, at 4° C. to 50° C. and samples taken for analysis of formoterol content at appropriate intervals.
  • a matrix of formulations containing 1.44 mg (12 ⁇ g/100 ⁇ l) formoterol fumarate were prepared in HFA 134a containing 12.0% w/w ethanol with or without 1.0% w/w isopropyl myristate as non-volatile excipient. Aliquots of drug concentrate were transferred to anodised cans and 3.15 to 3.35 ⁇ l of 1.0M hydrochloric acid added prior to crimping with 50 ⁇ l valves and gassing; between 22 and 28 replicates at each acid strength were prepared.
  • pMDI coated cans containing 3.25 ⁇ l 1.0 M hydrochloric acid were set down on storage inverted, at 4° C. and samples taken for analysis of formoterol and BDP contents at appropriate intervals.
  • TA 2005 (3.5 ⁇ g/50 ⁇ l) were prepared by dissolving 0.84 mg of the active ingredient in HFA 134a containing 12% w/w ethanol and 1.0% w/w of ispropyl myristate.
  • pMDI coated cans containing 1.0, 1.4, and 1.8 ⁇ l 0.08 M hydrochloric acid (corresponding respectively to an apparent pH of about 4.8, 3.2, and 2.9) were set down on storage, upright at 50° C., and samples taken for analysis of TA 2005 contents at appropriate intervals.
  • the solution formulation contained BDP (100 ⁇ g) and FF (6 ⁇ g) per 50 ⁇ l dose in HFA 134a propellant vehicle with 12% w/w ethanol as cosolvent and 0.024% w/w hydrochloric acid (1M) as stabiliser.
  • the formulation was packed in cans fitted with 50 ⁇ l valves and fired using a 0.30 mm actuator. Aerodynamic particle size assessments were conducted using an Andersen Cascade Impactor fitted with a USP induction port at the beginning and end of can-use life from each of two batches. Each determination was obtained by sampling 15 consecutive doses at a sampling flow rate of 28.31/min.
  • the delivered dose was determined using DUSA methodology (Dose Unit Spray Apparatus) at the beginning, middle and end of can-use life. Quantification of BDP and FF within test samples was performed using a HPLC method. Metered dose, delivered dose, fine particle dose, fine particle fraction, mass median aerodynamic diameter (MMAD), and geometric standard deviation (GSD) for each impactor measurement were calculated.
  • DUSA methodology Dose Unit Spray Apparatus
  • MMAD mass median aerodynamic diameter
  • GSD geometric standard deviation
  • the mean ratio of BDP to FF presented in Table 7 is 17.6 ⁇ 0.6, which is consistent with the ratio of metered BDP and FF (17.6 ⁇ 0.6).
  • the consistent ratio of the drug masses over the size fractions implies that each particle generated during the atomisation process contains drug concentrations consistent with the liquid properties of the product's solution formulation, and that this consistency is maintained for the residual particles following excipient evaporation, such that the measured particle size distributions for both resident drugs are identical.
  • the LABA is present in the combination at a strength 1 ⁇ g/actuation while the ICS is present at 100 ⁇ g/actuation within an acidified ethanol solution pressurized with HFA 134a.
  • Aerodynamic assessment of fine particles was performed by sampling 10 consecutive doses from each pMDI into an ACI.
  • the impactor was fitted with a USP induction port and operated at a sampling flow rate of 28.3 l/min.
  • Three pMDIs were tested (from the beginning, middle, and end of batch) and were tested at the beginning and end of life.
  • Drug deposition within the impactor was quantified using an HPLC assay.
  • the fine particle dose (FPD) was determined by summation of the drug collected on the ACI stages between S3 and filter.
  • Table 8 summarizes the deposition of the LABA and the ICS on the individual stages of the ACI.
  • the nominal dose of the combination pMDI was 1 ⁇ g LABA: 100 ⁇ g ICS.
  • FIG. 4 summarizes these results expressed as the % metered dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for delivering two or more active drug substances to the lungs by inhalation from a single pressurized metered dose inhaler product, said inhaler containing a HFA/cosolvent based solution formulation wherein all the active drug substances are fully dissolved in the formulation.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The invention relates to pharmaceutical solution to be used with pressurised metered dose inhalers (pMDIs) suitable for aerosol administration. In particular, the invention relates to aerosol solution formulations to be used with pressurised metered dose inhalers (pMDIs), suitable for the administration of a medicament to the lungs, said medicament comprising two or more active drug substances. More particularly, the invention relates to a method for delivering two or more active drug substances to the lungs by inhalation from a single inhaler. In a preferred embodiment one of the drug substances is a long-acting β2-agonist.
  • 2. Discussion of the Background
  • Treatment of pulmonary disease with inhaled aerosol drugs offers advantages over systemic therapy, including a more rapid onset and reduced adverse effects, because of direct targeting of the lungs.
  • Pressurised metered dose inhalers (pMDIs) are well known devices for administering pharmaceutical products to the respiratory tract by inhalation. MDI uses a propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol. Formulations for aerosol administration via MDIs can be solutions or suspensions. Solution formulations offer the advantage of being homogeneous with the active ingredient and excipients completely dissolved in the propellant vehicle or its mixture with suitable co-solvents such as ethanol. Solution formulations also obviate physical stability problems associated with suspension formulations so assuring more consistent uniform dosage administration.
  • For many years the preferred propellants used in aerosols for pharmaceutical use have been a group of chlorofluorocarbons which are commonly called Freons or CFCs, such as CCl3F (Freon 11 or CFC-11), CCl2F2 (Freon 12 or CFC-12), and CClF2-CClF2 (Freon 114 or CFC-114).
  • Recently, the chlorofluorocarbon (CFC) propellants such as Freon 11 and Freon 12 have been implicated in the destruction of the ozone layer and their production is being phased out.
  • Hydrofluoroalkanes [(HFAs) known also as hydro-fluoro-carbons (HFCs)] contain no chlorine and are considered less destructive to ozone and these are proposed as substitutes for CFCs.
  • HFAs and in particular 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants and a number of medicinal aerosol formulations using such HFA propellant systems have been disclosed.
  • Drugs commonly delivered by inhalation include short-acting and long-acting β2-agonists, anticholinergics/antimuscarinic agents, and corticosteroids.
  • Long-acting β2-Adrenoceptor agonists and antimuscarinic agents, in particular selective muscarinic receptors M3 antagonists, are the most effective bronchodilators, whereas corticosteroids are the most effective controllers of the underlying inflammatory process in the airways.
  • Recently, new broad spectrum anti-inflammatory drugs have been proposed, including phosphodiesterase-4 inhibitors or PDE4.
  • Examples of long-acting bronchodilator β2-agonists belonging to the class of the phenylalkylamino derivatives are formoterol, salmeterol and 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone (also referred to as carmoterol). Asthma and chronic obstructive pulmonary disease (COPD) are the most common broncho-pulmonary diseases and represent a major public health problem.
  • Asthma is a disease characterized by airway inflammation and smooth muscle dysfunction. Therefore to achieve optimum asthma control, therapy should be targeted against these underlying components.
  • The combination of a long-acting inhaled β2-agonist (LABA) and an inhaled corticosteroid (ICS) has been shown to improve lung function and to control asthma exacerbations in a more effective way than doubling the dose of ICS in patients with different degrees of asthma severity.
  • Bronchodilator therapy is the first step treatment in patients with COPD, but current guidelines recommend the addition of inhaled corticosteroids to bronchodilators.
  • As far as anticholinergics and beta-agonists are concerned, they reduce bronchoconstriction through different mechanism, and there is a long history of combination therapy in the past with short-acting agents in these classes for chronic obstructive pulmonary disease. More effective drug combinations may allow lower doses and thereby improve safety.
  • Therefore, it would be highly advantageous to provide a method and formulations in the form of HFA solution to be administered by MDI's aimed at providing pharmaceutical doses of two or more bronchodilating and/or anti-inflammatory compounds to the lung and especially a β2-agonist in combination with at least a further active compound for a more efficacious treatment of broncho-pulmonary diseases, in particular asthma and COPD.
    • SUMMARY OF THE INVENTION
  • Accordingly, it is one object of the present invention to provide novel formulations in the form of HFA solution to be administered by MDI's for providing pharmaceutical doses of active substances, preferably comprising a β2-agonist, into the low respiratory tract of patients suffering from pulmonary diseases such as asthma and COPD.
  • It is another object of the present invention to provide novel methods for preparing a pMDI which contains such a formulation.
  • It is another object of the present invention to provide novel methods for providing pharmaceutical doses of active substances, preferably comprising a β2-agonist, into the low respiratory tract of patients suffering from pulmonary diseases such as asthma and COPD.
  • In particular, it is another object of the invention to provide novel formulations in the form of HFA solution to be administered by MDI's for providing pharmaceutical doses of a long acting β2-agonist in combination with at least a further active ingredient, wherein both the long acting β2-agonist and the additional active ingredient are fully dissolved in the formulation.
  • It is another object of the present invention to provide novel methods for preparing a PMDI which contains such a formulation.
  • It is another object of the present invention to provide novel methods for providing pharmaceutical doses of a long acting β2-agonist in combination with at least a further active ingredient, wherein both the long acting β2-agonist and the additional active ingredient are fully dissolved in the formulation.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same become better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:
  • FIG. 1 shows the titration curve normalised to the usual fill volume of a pMDI can (12 ml) resulting from Example 1(a);
  • FIG. 2 shows the pH profile for the titration experiment reported in Example 1(b);
  • FIG. 3 shows the cumulative % undersize BDP and FF mass distributions for the sample as determined in Example 6; and
  • FIG. 4 shows the percentage (of metered dose) ACI stage by stage deposition of LABA and ICS (bars represents Mean±SD; (n=6)) as measured in Example 7.
    • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • According to the present invention there is provided a pharmaceutical composition comprising two or more active substances and in particular a long acting β2-agonist belonging to the class of phenylalkylamino derivatives in solution in a liquefied HFA propellant and a co-solvent selected from pharmaceutically acceptable alcohols.
  • Active ingredients which may be used in the aerosol compositions of the invention are short- and long-acting β2-adrenergic agonists, preferably long-acting β2-adrenergic agonists such as formoterol, salmeterol, carmoterol and salts thereof and their combinations with other active ingredients, preferably selected from the group of corticosteroids or anticholinergic atropine-like derivatives, antimuscarinic M3 inhibitors or phosphodiesterase 4 (PDE4) inhibitors.
  • Preferred corticosteroids are beclomethasone dipropionate, budesonide and its 22R-epimer, rofleponide, ciclesonide, fluticasone propionate, mometasone furoate or triamcinolone and its ester such as triamcinolone acetonide.
  • Preferred anticholinergic atropine-like derivatives are ipratropium bromide, oxitropium bromide, tiotropium bromide or glycopyrronium bromide.
  • Preferred long acting β2-agonists are formoterol, carmoterol and salmeterol and salts thereof.
  • More preferably the first active ingredient is a long acting β2-agonists belonging to the formula sketched below
    Figure US20060257324A1-20061116-C00001
    wherein R is 1-formylamino-2-hydroxy-phen-5-yl (formoterol) or 8-hydroxy-2(1H)-quinolinon-5-yl (TA 2005) or one of their salts, solvates, solvates of the salts or stereoisomers.
  • It is preferred that the formulation be suitable for delivering a therapeutic amount of the active ingredient in one or two actuations. In a first embodiment the formulation will be suitable for delivering 6 to 12 μg/dose of formoterol fumarate. In another embodiment, the formulation will be advantageously suitable for delivering 0.5 to 8 μg/dose, preferably 1 to 4 μg/dose, more preferably from 1 to 2 μg/dose of carmoterol hydrochloride (TA 2005). As “dose” it is meant the amount of active ingredient delivered by a single actuation of the inhaler.
  • The formulation of the invention may further contain small amounts of a mineral acid to adjust the apparent pH to between 2.5 and 5.0.
  • The attribution ‘apparent’ is used, as pH is indeed characteristic of aqueous liquids where water is the dominant component (Mole Fraction>0.95). In relatively aprotic solvents, such as the HFA-ethanol vehicles used in these studies, protons are non-hydrated; their activity coefficients differ significantly from those in aqueous solution. Although the Nernst equation with respect to EMF applies and the pH-meter glass electrode system will generate a variable milli-volt output according to proton concentration and vehicle polarity, the “pH” meter reading is not a true pH value. The meter reading represents an apparent pH or acidity function (pH′).
  • When formoterol fumarate was titrated with a strong acid in a model vehicle system commercially available (HFA 43-10MEE, Vertrel XF, Dupont), according to a method developed by the applicant, the pH′ profile exhibits a shallow negative to about pH′=5.5; thereafter the acidity function drops abruptly. Surprisingly the corresponding HFA formulations turned out to much more stable below pH′ 5.5. As far as TA 2005 is concerned, the pH′ profile exhibits a shallow negative to about pH′=5.0; thereafter the acidity function drops quite abruptly.
  • The formulations of the invention may be contained in a pressurized MDI having part of all of the internal metallic surfaces made of anodised aluminium, stainless steel or lined with an inert organic coating. Examples of preferred coatings are epoxy-phenol resins, perfluoroalkoxyalkane, perfluoroalkoxyalkylene, perfluoroalkylenes such as polytetrafluoroethylene, fluorinated-ethylene-propylene, polyether sulfone and a mixture of fluorinated-ethylene-propylene and polyether sulfone. Other suitable coatings could be polyamide, polyimide, polyamideimide, polyphenylene sulfide or their combinations.
  • To further improve the stability, cans having a rolled-in rim and preferably a part or full rollover rim may be used.
  • In fact, the chemical stability of certain active ingredients in HFA solution formulations can be dramatically improved by a proper selection of the can. On the other hand, the use of inert containers reduces the leaching of metal ions or alkali as a consequence of the action of the acid contained in the formulation on the inner walls of the cans. Metal ions such Al3+ or alkali respectively deriving from the conventional aluminium or glass cans could in turn catalyse radical oxidative or other chemical reactions of the active ingredient which give rise to the formation of degradation products.
  • The pharmaceutical composition may further contain a low volatility component, further improving the stability of the formulation. In fact, the addition of a low volatility component with a reduced polarity with respect to the co-solvent such as an ester may allow either to reduce the amount of acid to be added for adjusting the pH and diminish the polarity of the medium so limiting the possible uptake of environmental water. In the case of active ingredients such as formoterol, it is well known that the latter (e.g., humidity) could be detrimental to the stability of the active ingredient during storage. According to a particular embodiment of the invention, there is provided a pressurised MDI for administering pharmaceutical doses consisting of a container filled with a pharmaceutical composition comprising a long-acting β2 agonist selected from formoterol fumarate in solution in HFA 134a as a propellant in turn containing from 5% to 20%, preferably from 6% to 15% w/w ethanol as a co-solvent, the apparent pH of said solution having been adjusted to between 3.0 and 3.5 by addition of small amounts of hydrochloric acid. The expression ‘% w/w’ means the weight percentage of the component in respect to the total weight of the composition.
  • In another particular embodiment of the invention, there is provided a pressurised MDI filled with a pharmaceutical composition consisting of a solution comprising formoterol fumarate in combination with a corticosteroid in HFA 134a as a propellant in turn containing from 6% to 15% w/w, preferably 12% w/w ethanol as a co-solvent, the apparent pH of said solution having been adjusted to between 3.0 and 3.5 by addition of small amounts of hydrochloric acid.
  • In a preferred embodiment the corticosteroid is beclometasone dipropionate.
  • According to a further particular embodiment of the invention, there is provided a pressurised MDI consisting of a coated container filled with a pharmaceutical composition consisting of a solution of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxy-phenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone hydrochloride (TA 2005) in combination with a corticosteroid in HFA 134a as a propellant in turn containing from 6% to 15% w/w, preferably 12% w/w ethanol as a co-solvent, the apparent pH of said solution having been adjusted to between 3.0 and 5.0 by addition of small amounts of a mineral acid.
  • In a preferred embodiment the corticosteroid is budesonide or an epimer thereof.
  • WO 97/47286, EP 513127, EP 504112, WO 93/11747, WO 94/21228, WO 94/21229, WO 96/18384, WO 96/19198, WO 96/19968, WO 98/05302, WO 98/34595, and WO 00/07567 disclose HFA formulations in the form of suspensions in which β2-agonists such formoterol and salbutamol are either exemplified and/or claimed.
  • WO 99/65464 refers to HFA formulations containing two or more active ingredients in which at least one is in suspension. The preferred formulations comprise salbutamol sulphate in suspension.
  • WO 98/34596 describes solution compositions for use in an aerosol inhaler, comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent and further comprising a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. Said application does not address the technical problem of the chemical stability of the active ingredient but it rather concern the drug delivery to lungs.
  • International Application No. PCT/EP99/09002 filed on 23 Nov. 1999 published on Jun. 2, 2000 as WO 00/30608 discloses pressurised MDI's for dispensing a solution of an active ingredient in a hydrofluorocarbon propellant, a co-solvent and optionally a low-volatility component characterised in that part or all of the internal surfaces of said inhalers consist of stainless steel, anodised aluminium or are lined with an inert organic coating. The examples are referred only to steroids and anticholinergic agents.
  • EP 673240 proposes the use of acids as stabilisers preventing the chemical degradation of the active ingredient in aerosol solution formulations comprising HFAs. Most examples relate to ipratropium bromide, an anticholinergic drug and only an example is presented for a β2-agonist, i.e. fenoterol. Although salbutamol is claimed, no exemplary formulations are provided. Moreover, the stability data are reported only for ipratropium and the patentee does not distinguish between the use of organic and inorganic acids. Furthermore, apart from ipratropium bromide, in EP 673240 no guidance is given with respect to the amount of acid which has to be added in order to stabilise the medicaments without compromising the stability of the whole composition in the can. The only hint can be found on page 5, lines 15 to 16 which says that an amount of inorganic acid should be added to obtain a pH value from 1 to 7, so a very broad and generic range.
  • WO 98/34596 refers to solution formulations containing a propellant and a physiologically acceptable polymer which could help the solubilisation and the stability as well of the active ingredients.
  • WO 00/06121 refers to propellant mixtures for aerosol dinitrogen monoxide and a hydrofluoroalkane in the preparation of suspension and solution aerosols. The use of dinitrogen monoxide may improve the stability at storage of oxidation-sensitive active ingredients. As far as β2-agonist such as levosalbutamol sulphate, formoterol fumarate and salmeterol xinafoate, only examples referred to suspensions are reported.
  • WO 99/65460 claims pressurised MDI's containing stable formulations of a β-agonist drug in suspension or solution. Examples refer to solutions of formoterol fumarate containing an HFA propellant and ethanol as co-solvent, filled in conventional aluminium or plastic coated glass cans. Samples stored under accelerated conditions (40° C, 75% relative humidity) for a very short period, one month, exhibited about 10% loss of drug. According to pharmaceutical guidelines on stability, loss of 10% of active ingredient does not meet the criteria of acceptance. Moreover, as it is evident from the data reported in Example 2 of the present application, following the teaching of WO 99/65460 stable formoterol solution formulations cannot be provided.
  • WO 03/074025 refers to a pharmaceutical aerosol formulation to be administered by pressurized metered dose inhalers which comprises as active ingredient a long acting β2-agonist selected from a 2(1H)-quinolinone derivative, a stereoisomer, physiologically acceptable salt and solvate thereof, in a solution consisting of a liquefied HFA propellant, a co-solvent and optionally an amount of water up to 5% on the total weight of the formulation.
  • The formulation is able to deliver, on actuation of the inhaler, a fraction of superfine particles equal to or less than 1.1 micron up to 50% or more so allowing the drug to reach the small peripheral airways region where it exercises its pharmacological effects.
  • WO 2004/075896 refers to a combined preparation comprising:
      • 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl-2(1H)-quinolinone or a physiologically acceptable salt or solvate thereof;
      • at least a further active ingredient useful for the treatment of the inflammatory or obstructive airways disease, for the simultaneous, sequential or separate use in the treatment of an inflammatory or obstructive airways disease.
  • One of the preferred combination products comprises the hydrochloride salt CHF 4226 and a corticosteroid: it has indeed been found that, in such a combination, both the bronchodilator and the anti-inflammatory effects increase.
  • According to a further aspect of the invention there is provided a method of preparing a filled device, such as an aerosol inhaler, with a composition of the invention, the method comprising:
      • (a) Preparing of a solution of one or more active ingredients in one or more co-solvents optionally containing an appropriate amount of a low volatility component;
      • (b) Filling of the device with said solution;
      • (c) Adding a pre-determined amount of a strong mineral acid;
      • (d) Adding a propellant containing a hydrofluoroalkane (HFA); and
      • (e) Crimping with valves and gassing.
  • The formulation is actuated by a metering valve capable of delivering a volume of between 50 μl and 100 μl.
  • Metering valves fitted with gaskets made of chloroprene-based rubbers can preferably be used to reduce the ingress of moisture which, as previously mentioned, can adversely affect the stability of the drug during storage. Optionally, further protection can be achieved by packaging the product in a sealed aluminium pouch.
  • The hydrofluorocarbon propellant is preferably selected from the group of HFA 134a, HFA 227 and mixtures thereof.
  • The co-solvent is usually an alcohol, preferably ethanol.
  • The low volatility component, when present, has a vapour pressure at 25° C. lower than 0.1 kPa, preferably lower than 0.05 kPa. Advantageously, it could be selected from the group of glycols, particularly propylene glycol, polyethylene glycol and glycerol or esters, for example ascorbyl palmitate, isopropyl myristate and tocopherol esters.
  • The compositions of the present invention may contain from 0.1 to 10% w/w of said low volatility component, preferably between 0.3 to 5% w/w, more preferably between 0.4 and 2.0% w/w.
  • Propylene glycol, polyethylene glycol, glycerol with residual water less than 0.1% w/w and esters of long-chain fatty acids are the preferred low-volatility components. More preferred are those with a dipole moment less than 2.0 or with a dielectric static constant less than 20, preferably less than 10. Particularly preferred is isopropyl myristate.
  • The function of the low volatility component is to modulate the MMAD of the aerosol particles and optionally to further improve the stability of the formulation. With respect to the latter aspect, particularly preferred is the use of isopropyl myristate.
  • The apparent pH range is advantageously comprised between 2.5 and 5.0, preferably between 3.0 and 5.0. Strong mineral acids such as hydrochloric, nitric, sulphuric or phosphoric are preferably used to adjust the apparent pH.
  • The amount of acid to be added to reach the desired apparent pH will be pre-determined in the model vehicle reported before. In the case of the formulation of formoterol fumarate and its combination with beclometasone dipropionate, an amount comprised between 3 and 3.5 μl of 1.0 M hydrochloric acid should be added to obtain an apparent pH between 3.0 and 3.5.
  • As said before, co-deposition within the lung of a combination of two or more drugs may result in a clinical response that is greater than the sum of the response of the individual drugs administered. A recommended combination is the combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) bronchodilator in the treatment of persistent asthma, to provide both anti-inflammatory and bronchodilating effects.
  • Nelson et al, in J. Allergy Clin. Immunol., 2003, 112, 29-36, hypothesized that fluticasone propionate and salmeterol in the form of a solid powder delivered simultaneously through a single dry powder inhaler can avoid deposition variation caused by natural variation in inspiratory manoeuvres on successive inhalation and might co-deposit in the airways.
  • The potential effect has been ascribed to the tendency of the two drugs to form particle agglomerations within the inhaler device.
  • On the other hand, when two active drug substances are present in the formulation as a dry powder, the size of the solid particles can be easily pre-determined by the micronization process.
  • A higher degree of co-deposition following the combined administration of two drugs has been found also by using a single metered dose inhaler containing salmeterol xinafoate and fluticasone propionate both in the form of solid particles suspended in the HFA propellant. Also in this case the effect has been ascribed to the formation of particle agglomerations (Intern. J. Pharmaceutics, 2006, 313, 14-22).
  • Clinical advantages are therefore inherent within inhalation products that can deliver a combination of two or more drugs as a single administration.
  • Co-deposition in the same lung region could maximize the synergistic effects, but the two active ingredients have to show exactly the same distribution profile.
  • It has now been found that in the pressurized metered dose inhaler product of the invention, comprising an ethanol/HFA propellant based solution formulation for aerosol administration containing a combination of two or more active drug substances, wherein said active drug substances are fully dissolved in the formulation, each liquid particle generated during the MDIs atomisation process contains drug concentrations consistent with the liquid properties of the product's solution formulation and that this consistency is maintained for the residual particles following excipient evaporation. In other words, substantially all of the liquid particles emitted on actuation of the inhaler contain the two or more drug substances in a ratio which is substantially the same as the ratio of the two or more drug substances in the solution formulation contained in the inhaler. Thus, preferably at least 85%, preferably at least 90%, more preferably at least 95%, even more preferably at least 98%, even more preferably at least 99%, of the liquid droplets emitted on actuation of the inhaler contain the two or more drug substances in a ratio (when expressed as a ratio obtained by dividing the mass of the major component by the mass of the minor component) which preferably differs by less than 15%, preferably less than 10%, more preferably less than 5%, even more preferably less than 2%, even more preferably less than 1%, from the ratio of the two or more drug substances in the solution formulation contained in the inhaler. In this regard, the ratio of the two or more drug substances in the solution formulation will in part depend on the identity of the drug substances and the condition and subject being treated. However, in view of the teachings of the present specification, determination of such ratios is within the abilities of those skilled in the art. In particular, for formoterol fumarate and beclometasone dipropionate, the mass ratio of beclometasone to formoterol fumarate may preferably be 100:0.1 to 100:50, more preferably 100:1 to 100:20, even more preferably 100:2 to 100:10. For carmoterol hydrochloride and budesonide, the mass ratio of budesonide to carmoterol hydrochloride may preferably be 100:0.01 to 100:15, more preferably 100:0.05 to 100:10, even more preferably 100:0.1 to 100:7, even more preferably 100:0.5 to 100:5, even more preferably 100:0.5 to 100:4, even more preferably 100:0.5 to 100:3.
  • It has unexpectedly been found that each droplet of the aerosol cloud emitted on actuation of the inhaler containing a solution of different active drug substances dries to give particles of the active materials with identical size distributions in the correct ratio. In other words, the liquid droplets dry to give particles of the two or more drug substances, and the particles of the two or more drug substances have substantially the same particle size distribution. Thus, the fine particle fractions (at ≦5 μm) of the two or more drug substances preferably differ by less than 15%, preferably less than 10%, more preferably less than 5%, even more preferably less than 2%, even more preferably less than 1%. In addition, the fine particle fractions (at ≦1 μm) of the two or more drug substances preferably differ by less than 15%, preferably less than 10%, more preferably less than 5%, even more preferably less than 2%, even more preferably less than 1%.
  • This characteristic is maintained through the entire container life.
  • This is even more surprising in consideration of the fact that the active substances have different chemico-physical and solubility characteristics, and are present in the formulation in very different concentrations and dosage strengths. Moreover, the spray cloud of finely divided liquid particles dispersed in a gas stream emitted from the MDI, is a dynamic system quickly evaporating and moving through the air way from the actuator.
  • Therefore the invention is particularly directed to a method for delivering two or more active drug substances to the lung by inhalation from a single pressurized metered dose inhaler product, said inhaler containing a HFA/cosolvent based solution formulation wherein all the active drug substances are fully dissolved in the formulation.
  • The particle size distribution (PSD) data for two different combinations of LABA and ICS within an ethanol based solution HFA pMDI, has been measured using an Andersen Cascade Impactor (ACI) in accordance with the European guidelines.
  • Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
    • EXAMPLES Example 1 Effect of Hydrochloric Acid on Solution pH′ (Acidity Function)
  • (a) 1.0 M hydrochloric acid was added incrementally to 50 ml of HFA 43-10MEE (Vertrel XF) containing 20% w/w ethanol and the pH′ was measured after each aliquot of acid. FIG. 1 shows the resultant titration curve normalised to the usual fill volume of a pMDI can (12 ml). The pH′ profile exhibits a shallow negative slope to about pH′=5.5; thereafter the acidity function drops abruptly.
  • (b) Experiment (a) was repeated with formoterol formulations containing a lower concentration of ethanol (12% w/w) and with the addition of 1.0% isopropyl myristate. The resultant pH profile, for replicate bulk solutions, shown in FIG. 2 is similar in shape with the abrupt fall in pH′ per unit increment of acid again commencing at about pH′=5.5. However, only about half the acid is required to achieve the same reduction in pH′. This is largely due to the reduction in ethanol content; FIG. 2 also shows similarity in the profiles obtained with and without isopropyl myristate.
    • Example 2 Effect of pH′ on Stability of Formoterol Solutions in HFA 43-10MEE containing 20% w/w Ethanol
  • Aliquots of 1.0 M hydrochloric acid were added to 12 ml of formoterol solution in glass vials. After measurement of pH, valves were crimped on and the vials stored upright at 50° C. Vial samples containing different concentrations of acid were assayed for residual formoterol after 10 and 20 days storage. The pH′ of a third vial was determined after 40 days storage. The results are shown in Table 1. Table 1 shows changes in pH on storage; this is probably largely associated with leaching of alkali from the soft glass of the vials. However, overall consideration of the pH′ and formoterol content data implies that the stability of a solution formulation of the drug in HFA can be improved by the addition of mineral acid to provide a formulation with pH′ between 2.5 to 5.0.
    TABLE 1
    pH′ and Formoterol Content of Formoterol-Vertrel XF/HFA Solutions
    (12 μg/100 μl)
    Vehicle: Vertrel XF/HFA with 20% Ethanol and Hydrochloric Acid
    St Gobain glass vials stored upright
    Acidity Percent Residual
    Function (pH′) Conc. Formoterol
    Initial 40 days Initial 10 days 20 days
    1.8 2.8 100 4.8 Nil
    2.1 4.4 100 75.1 70.7
    2.6 4.2 100 97.2 86.7
    3.3 4.2 100 97.1 89.9
    5.6 6.6 100 95.8 92.1
    7.4 6.7 100 85.4 67.2
    • Example 3 Stability of Acidified Formoterol-HFA 134a Solutions in Anodised Cans
  • Formoterol formulations (12 μg/100 μl) were prepared by dissolving 1.44 mg of formoterol fumarate in HFA 134a containing 12% w/w ethanol with and without 1.0% w/w isopropyl myristate. The latter was included as a non-volatile excipient with the potential for increasing MMAD if so desired. It also improves the solubility of formoterol in the vehicle and reduces polarity of the vehicle compared to the addition of glycerol.
  • pMDI cans containing 3.1 to 3.4 μl 1.0 M hydrochloric acid were set down on storage, upright and inverted, at 4° C. to 50° C. and samples taken for analysis of formoterol content at appropriate intervals.
  • Stability data obtained after 70 days of storage are given in Table 2.
  • A matrix of formulations containing 1.44 mg (12 μg/100 μl) formoterol fumarate were prepared in HFA 134a containing 12.0% w/w ethanol with or without 1.0% w/w isopropyl myristate as non-volatile excipient. Aliquots of drug concentrate were transferred to anodised cans and 3.15 to 3.35 μl of 1.0M hydrochloric acid added prior to crimping with 50 μl valves and gassing; between 22 and 28 replicates at each acid strength were prepared.
  • To determine residual formoterol, 30×50 μl shots were discharges into DUSA tubes. The acid range selected was anticipated to give pH′ values of 3.0 to 3.5 and to determine the formulation sensitivity to small changes in acid concentration. Cans were placed on stored upright and inverted (valve up and down respectively) at 25 to 50° C. Table 2 shows the results obtained at 40° C. and 50° C. after 11 to 40 day's storage. Each value (expressed as per cent nominal drug concentration) is obtained from a different can. Initial values were obtained for two cans of each acid strength. Inspection of the data shows that all assay values are within the reproducibility of the HPLC assay and independent of acid strength. A similar conclusion was drawn for the storage time point replicates, i.e., independent of acid strength (3.2 to 3.3 μl) or whether cans were stored upright or inverted. Consequently for kinetics calculation the mean value for initial (n=10) and subsequent time points (n=6) was used.
  • In Table 3 are reported the Arrhenius parameters together with estimated shelf lives at 4, 10, and 25° C. The t5% is predicted to be greater than 3 months at ambient temperature and approximately 2 years at 4° C.
    TABLE 2
    Stability Data for Formoterol Fumarate Solutions (12 μg/100 μl) in HFA
    134a containing 12.0% Ethanol ± 1.0% Isopropyl Myristate (values are
    expressed as percent nominal)
    Anodised cans fitted with 50 μl valves/30 doses collected per can
    Different cans assessed at each condition
    Cans stored upright (* inverted)
    STORAGE CONDITION/No isopropyl myristate
    1.0M HCl Initial 40° C.; 40 days 50° C.; 11 days 50° C.; 33 days
    μl per Can 1st Can 2nd Can 1st Can 2nd Can 1st Can 2nd Can 1st Can 2nd Can
    3.15 99.8 99.6 — — — — — —
    3.20 100.8 99.7 96.0 93.2* 96.7 96.5 88.5 89.9*
    3.25 97.9 98.8 93.9 94.3* 96.4 96.5 92.2 91.5*
    3.30 97.3 98.9 93.7 93.7* 97.0 89.1 90.9 92.8*
    3.35 100.0 98.3 — — — — — —
    Mean 99.1 94.1 95.4 91.0
    C.V. 1.1% 1.0% 3.2% 1.8%
    STORAGE CONDITION/1.0% isopropyl myristate
    1.0M Hcl Initial 40° C.; 33 days 50° C.; 11 days 50° C.; 31 days
    μl per Can 1st Can 2nd Can 1st Can 2nd Can 1st Can 2nd Can 1st Can 2nd Can
    3.15 101.1 99.3 — — — — — —
    3.20 97.0 100.2 94.4 93.2* 93.8 93.6 90.6 92.7*
    3.25 101.4 100.2 98.6 95.0* 96.1 95.9 91.6 89.7*
    3.30 99.9 100.8 92.8 95.3* 95.6 95.7 90.0 89.6*
    3.35 99.2 97.2 — — — — — —
    Mean 99.6 94.9 95.1 90.7
    C.V. 1.5% 2.2% 1.2% 1.4%
  • TABLE 3
    Shelf Life Prediction for Acidified Formoterol Fumarate Solution
    (12 μg/100 μl) in HFA 134a containing 12% w/w Ethanol ± 1.0% w/w
    isopropyl Myristate (IPM)
    Anodised aluminium cans
    FORMOTEROL FUMARATE (percent nominal)
    Time 40° C.
    (days) Nil IPM 1% IPM Nil IPM 1% IPM
     0 99.1 99.6 99.1 99.6
    11 95.4 95.1 — —
    31 — 90.7 — —
    33 91.0 — — 94.9
    40 — — 94.1 —
    Rate Const. 2.52 2.94 1.29 1.46
    (day−1 × 103)
    Frequency Activation
    Arrhenius Parameters Factor (day−1) Energy (kJ mol−1)
    Nil IPM 3.19 × 106 56.3
    1% w/w IPM 9.63 × 106 58.9
    Nil IPM 1.0% w/w IPM
    Temper- Rate Const. t10% Rate Const. t10%
    ature (day−1) (days) t5% (day−1) (days) t 5%
     4° C. 7.8 × 10−5 1344 657 7.8 × 10−5 1360 664
    10° C. 1.3 × 10−4 802 392 1.3 × 10−4 789 386
    25° C. 4.4 × 10−4 240 117 4.4 × 10−4 225 110
    • Example 4 Stability of Acidified Formoterol/BDP-HFA 134a Solutions in Cans Coated with a Fluorocarbon Polymer (DuPont 3200-200)
  • Formoterol and BDP combination formulations equivalent to doses of 6 μg/50 μl and 100 μg/50 l respectively, were prepared by dissolving 1.44 mg of formoterol fumarate and 24 mg of BDP in HFA 134a containing 12% w/w ethanol and 0.4% w/w of isopropyl myristate. pMDI coated cans containing 3.25 μl 1.0 M hydrochloric acid were set down on storage inverted, at 4° C. and samples taken for analysis of formoterol and BDP contents at appropriate intervals.
  • Stability data obtained are given in Table 4.
  • Each value is expressed as per cent nominal drug concentration.
  • The results indicate that the formulation is stable for at least 4 months at 4° C.
    • Example 5 Stability of Acidified TA 2005-HFA 134a Solutions in Cans Coated with a Fluorocarbon Polymer (DuPont 3200-200)
  • TA 2005 (3.5 μg/50 μl) were prepared by dissolving 0.84 mg of the active ingredient in HFA 134a containing 12% w/w ethanol and 1.0% w/w of ispropyl myristate. pMDI coated cans containing 1.0, 1.4, and 1.8 μl 0.08 M hydrochloric acid (corresponding respectively to an apparent pH of about 4.8, 3.2, and 2.9) were set down on storage, upright at 50° C., and samples taken for analysis of TA 2005 contents at appropriate intervals.
  • Stability data obtained are given in Table 5.
  • Each value is expressed as per cent nominal drug concentration.
  • The results indicate that the formulations in which the apparent pH is comprised between 3.0 and 5.0 are stable (i.e. give rise to much less than 10% loss of drug) for almost three months at 50° C., while that corresponding to an apparent pH of less than 3, is not.
    TABLE 4
    Formoterol/BDP combination formulations of Example 4 - Stability
    data at 4° C.
    Storage Condition
    4° C.; 64 days 4° C.; 123 days
    Initial inverted inverted
    Formoterol 104.7 95.10 99.9
    BDP 99.4 100.10 102.6
  • TABLE 5
    TA 2005 formulations of Example 5 - Stability data at 50° C.
    Storage Condition
    0.08M HCl 50° C.; 22 days 50° C.; 83 days
    μl per can Initial upright upright
    1.0 100.0 98.3 99.4
    1.4 100.0 98.2 98.8
    1.8 100.0 90.2 88.1
    • Example 6 Particle Size Distribution for Formoterol Fumarate and Beclometasone Dipropionate within an Ethanol Based Solution HFA pMDI by Andersen Cascade Impactor (ACI)
  • The solution formulation contained BDP (100 μg) and FF (6 μg) per 50 μl dose in HFA 134a propellant vehicle with 12% w/w ethanol as cosolvent and 0.024% w/w hydrochloric acid (1M) as stabiliser. The formulation was packed in cans fitted with 50 μl valves and fired using a 0.30 mm actuator. Aerodynamic particle size assessments were conducted using an Andersen Cascade Impactor fitted with a USP induction port at the beginning and end of can-use life from each of two batches. Each determination was obtained by sampling 15 consecutive doses at a sampling flow rate of 28.31/min. For each can tested the delivered dose was determined using DUSA methodology (Dose Unit Spray Apparatus) at the beginning, middle and end of can-use life. Quantification of BDP and FF within test samples was performed using a HPLC method. Metered dose, delivered dose, fine particle dose, fine particle fraction, mass median aerodynamic diameter (MMAD), and geometric standard deviation (GSD) for each impactor measurement were calculated.
  • Delivery performance derived from impactor measurements are summarised in Table 6. For BDP and FF respectively, the mean delivered dose values obtained from the impactor measurements were within 95 to 100% and 91 to 101% of the mean values obtained using DUSA methodology. The consistency in the fine particle fraction (both≦5 μm and ≦1 μm), MMAD and GSD for BDP and FF is a consequence of the similar particle size distributions of the two drugs as shown in FIG. 3.
    TABLE 6
    Summary of Delivery Performance Characteristics (n = 4)
    Drug BDP FF
    Metered Dose, MD (μg) 94.5 ± 2.3 5.4 ± 0.3
    Delivered Dose (μg) 87.0 ± 2.2 4.9 ± 0.3
    Dose ≦5 μm (μg) 34.5 ± 1.1  1.9 ± <0.1
    Fraction ≦5 μm (%) 39.7 ± 2.2 38.6 ± 2.2 
    Dose ≦1 μm (μg) 11.1 ± 0.2  0.6 ± <0.1
    Fraction ≦1 μm (%) 12.8 ± 0.4 11.8 ± 0.5 
    MMAD (μm)  1.4 ± <0.1  1.5 ± <0.1
    GSD  2.0 ± 0.1 2.0 ± 0.1
    Shot Weight (mg) 54.0 ± 1.3
  • TABLE 7
    Drug Mass within Samples Containing >5% of the MD (n = 4)
    Ratio:
    BDP (μg) FF (μg) BDP/FF
    Actuator 7.5 ± 0.3 0.43 ± 0.03 17.6 ± 1.0
    Induction Port 49.5 ± 3.2  2.89 ± 0.23 17.1 ± 0.3
    Stage 4
    (2.1-3.3 μm) 5.9 ± 0.3 0.33 ± 0.01 17.8 ± 0.5
    Stage 5
    (1.1-2.1 μm) 14.2 ± 0.8  0.80 ± 0.03 17.7 ± 0.5
    Stage 6
    (0.65-1.1 μm) 6.4 ± 0.3 0.36 ± 0.01 17.8 ± 0.7
    Total: 83.6 ± 4.9  4.82 ± 0.32 Mean: 17.6 ± 0.6

    Table 7 presents the mean drug deposition for samples containing >5% of the metered dose, the total being representative of 94.5±5.4% of the total metered drug mass. The mean ratio of BDP to FF presented in Table 7 is 17.6±0.6, which is consistent with the ratio of metered BDP and FF (17.6±0.6). The consistent ratio of the drug masses over the size fractions implies that each particle generated during the atomisation process contains drug concentrations consistent with the liquid properties of the product's solution formulation, and that this consistency is maintained for the residual particles following excipient evaporation, such that the measured particle size distributions for both resident drugs are identical.
    • Example 7 Solution Combination Containing Carmoterol Hydrochloride as LABA and Budesonide as ICS
  • The LABA is present in the combination at a strength 1 μg/actuation while the ICS is present at 100 μg/actuation within an acidified ethanol solution pressurized with HFA 134a. Aerodynamic assessment of fine particles was performed by sampling 10 consecutive doses from each pMDI into an ACI. The impactor was fitted with a USP induction port and operated at a sampling flow rate of 28.3 l/min. Three pMDIs were tested (from the beginning, middle, and end of batch) and were tested at the beginning and end of life. Drug deposition within the impactor was quantified using an HPLC assay. The fine particle dose (FPD) was determined by summation of the drug collected on the ACI stages between S3 and filter.
  • Table 8 summarizes the deposition of the LABA and the ICS on the individual stages of the ACI. The nominal dose of the combination pMDI was 1 μg LABA: 100 μg ICS. FIG. 4 summarizes these results expressed as the % metered dose.
    TABLE 8
    ACI Stage by Stage deposition of LABA and ICS. Data represents
    Mean ± SD; (n = 6)
    Deposition Site LABA (μg) ICS (μg)
    Actuator 0.08 ± 0.02 6.68 ± 1.14
    Induction port 0.40 + 0.03 38.16 + 2.29 
    Stage 0 0.02 + 0.01 2.88 + 0.44
    Stage 1 0.01 + 0.01 1.22 + 0.34
    Stage 2 0.00 + 0.00 0.33 + 0.13
    Stage3 0.01 + 0.00 0.91 + 0.16
    Stage 4 0.05 + 0.01 5.45 + 0.83
    Stage 5 0.18 + 0.02 18.5 + 1.83
    Stage 6 0.11 + 0.01 10.8 + 0.75
    Stage 7 0.05 + 0.00 5.29 + 0.36
    Filter 0.05 + 0.00 6.10 + 0.60
  • TABLE 9
    Aerosol Performance of a Combination LABA: ICS HFA SOLUTION
    pMDI (n = 6)
    Delivered Dose Fine Particle Fine particle
    Active Mass balance (μg from ACI) Dose (μg) fraction (%)
    LABA 96.8% ± 3.6% 0.89 ± 0.03 0.45 ± 0.03 51.0% ± 3.0%
    ICS 96.3% ± 3.3% 89.7 ± 3.2  47.1 ± 2.7  52.5% ± 2.3%
  • The results demonstrate that the solution combination of the example provides fine particle fractions for the two components which are not statistically significantly different (p<0.05), despite the significantly different concentration of the two active drugs in the aerosol cloud. The ratio between the two active drugs is maintained in all the ACI stages allowing their co-deposition in the lungs, which could offer an increased opportunity for any synergistic interaction to occur.
  • Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that, within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.
  • All patents and other references mentioned above are incorporated in full herein by this reference, the same as if set forth at length.

Claims (26)

1. A method of delivering a combination of two or more active drug substances to at least one lung region tract of a subject in need thereof, comprising:
administering said two or more active drug substances to said subject by actuation of a pressurized single metered dose inhaler,
wherein said pressurized single metered dose inhaler contains a medicament which exists as a solution,
wherein said medicament comprises two or more active drug substances in a predetermined ratio dissolved in an HFA propellant and one or more co-solvents,
wherein at least one of said active drug substances is a long acting β2-adrenergic agonist,
wherein on actuation said inhaler emits liquid particles,
wherein substantially all of said liquid particles emitted on actuation of said inhaler contain said two or more active drug substances in a ratio which is substantially the same as said predetermined ratio of said two or more active drug substances in said medicament, and
wherein each of said two or more active drug substances is delivered with substantially the same particle size distribution at the same lung region tract.
2. A method according to claim 1, wherein said β2-adrenergic agonist is at least one member selected from the group consisting of formoterol, carmoterol, salmeterol, stereoisomers, a salt thereof, a solvate thereof, a solvate of a salt thereof, and mixtures thereof.
3. A method according to claim 2, wherein said medicament comprises a corticosteroid.
4. A method according to claim 3, wherein said corticosteroid is at least one member selected from the group consisting of beclomethasone dipropionate, fluticasone propionate, budesonide, the 22R-epimer of budesonide, rofleponide, ciclesonide, mometasone furoate, triamcinolone, an ester of triamcinolone, and mixtures thereof.
5. A method according to claim 4, wherein said ester of triamcinolone is triamcinolone acetonide.
6. A method according to claim 2, wherein said medicament comprises an anticholinergic atropine-like derivative or an antimuscarinic M3 inhibitor.
7. A method according to claim 6, wherein said anticholinergic atropine-like derivative is at least one member selected from the group consisting of ipratropium bromide, oxitropium bromide, tiotropium bromide, glycopyrronium bromide, and mixtures thereof.
8. A method according to claim 1, wherein said medicament comprises a phosphodiesterase 4 (PDE4) inhibitor.
9. A method according to claim 3, wherein said β2-adrenergic agonist is formoterol fumarate and said corticosteroid is beclometasone dipropionate.
10. A method according to claim 3, wherein said β2-adrenergic agonist is carmoterol hydrochloride and said corticosteroid is budesonide.
11. A method according to claim 1, wherein the HFA propellant comprises at least one member selected from the group consisting of HFA 134a, HFA 227, and mixtures thereof.
12. A method according to claim 1, wherein said co-solvent comprises an alcohol.
13. A method according to claim 1, wherein said co-solvent comprises ethanol.
14. A pressurized single metered dose inhaler,
wherein said pressurized single metered dose inhaler contains a medicament which exists as a solution,
wherein said medicament comprises two or more active drug substances in a predetermined ratio dissolved in an HFA propellant and one or more co-solvents,
wherein at least one of said active drug substances is a long acting β2-adrenergic agonist,
wherein on actuation said inhaler emits liquid particles,
wherein on actuation of said inhaler substantially all of said liquid particles emitted on actuation of said inhaler contain said two or more active drug substances in a ratio which is substantially the same as said predetermined ratio of said two or more active drug substances in said medicament, and
each of said two or more active drug substances is delivered with substantially the same particle size distribution at the same lung region tract.
15. An inhaler according to claim 14, wherein said β2-adrenergic agonist is at least one member selected from the group consisting of formoterol, carmoterol, salmeterol, stereoisomers, a salt thereof, a solvate thereof, a solvate of a salt thereof, and mixtures thereof.
16. An inhaler according to claim 15, wherein said medicament comprises a corticosteroid.
17. An inhaler according to claim 16, wherein said corticosteroid is at least one member selected from the group consisting of beclomethasone dipropionate, fluticasone propionate, budesonide, the 22R-epimer of budesonide, rofleponide, ciclesonide, mometasone furoate, triamcinolone, an ester of triamcinolone, and mixtures thereof.
18. An inhaler according to claim 17, wherein said ester of triamcinolone is triamcinolone acetonide.
19. An inhaler according to claim 15, wherein said medicament comprises an anticholinergic atropine-like derivative or an antimuscarinic M3 inhibitor.
20. An inhaler according to claim 19, wherein said anticholinergic atropine-like derivative is at least one member selected from the group consisting of ipratropium bromide, oxitropium bromide, tiotropium bromide, glycopyrronium bromide, and mixtures thereof.
21. An inhaler according to claim 14, wherein said medicament comprises a phosphodiesterase 4 (PDE4) inhibitor.
22. An inhaler according to claim 16, wherein said β2-adrenergic agonist is formoterol fumarate and said corticosteroid is beclometasone dipropionate.
23. An inhaler according to claim 16, wherein said β2-adrenergic agonist is carmoterol hydrochloride and said corticosteroid is budesonide.
24. An inhaler according to claim 14, wherein the HFA propellant comprises at least one member selected from the group consisting of HFA 134a, HFA 227, and mixtures thereof.
25. An inhaler according to claim 14, wherein said co-solvent comprises an alcohol.
26. An inhaler according to claim 14, wherein said co-solvent comprises ethanol.
US11/408,026 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers Abandoned US20060257324A1 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
US11/408,026 US20060257324A1 (en) 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2007241336A AU2007241336C1 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
DK07724357.4T DK2010190T3 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulation for pressurized, dose controlled inhalers
RS20130386A RS52940B (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
SI200731304T SI2010190T1 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
JP2009505773A JP5289306B2 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurized metered dose inhalers
EA200802012A EA016262B1 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurized metered dose inhalers
KR1020087018846A KR101311662B1 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurized metered dose inhalers
PT77243574T PT2010190E (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
MX2008013460A MX2008013460A (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers.
CA2649556A CA2649556C (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
BRPI0709510-4A BRPI0709510A2 (en) 2006-04-21 2007-04-19 pharmaceutical solution formulations for pressurized metered dose inhalers
CNA2007800069518A CN101389341A (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metereddose inhalers
EP07724357.4A EP2010190B1 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
PCT/EP2007/003420 WO2007121913A2 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
MEP-2016-22A ME02342B (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
CN201610483860.4A CN106074359A (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
CN201610428382.7A CN105963249A (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
PL07724357T PL2010190T3 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
CN2012103537724A CN102908308A (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers
ES07724357T ES2424753T3 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurized metered dose inhalers
ZA2008/08965A ZA200808965B (en) 2006-04-21 2008-10-20 Pharmaceutical solution formulations for pressurised metered dose inhalers
US12/255,075 US20090130026A1 (en) 2006-04-21 2008-10-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
CY20131100703T CY1114215T1 (en) 2006-04-21 2013-08-14 PHARMACEUTICAL SOLUTIONS FOR SOLID PRESSURE INHIBITORS
HRP20130835TT HRP20130835T1 (en) 2006-04-21 2013-09-09 Pharmaceutical solution formulations for pressurised metered dose inhalers
US15/353,978 US10525006B2 (en) 2006-04-21 2016-11-17 Pharmaceutical solution formulations for pressurised metered dose inhalers
US16/689,611 US11213485B2 (en) 2006-04-21 2019-11-20 Pharmaceutical solution formulations for pressurized metered dose inhalers

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
WOPCT/EP00/04635 2000-05-22
PCT/EP2000/004635 WO2001089480A1 (en) 2000-05-22 2000-05-22 Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US09/860,689 US6716414B2 (en) 2000-05-22 2001-05-21 Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US10/640,005 US7018618B2 (en) 2000-05-22 2003-08-14 Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US11/289,479 US20060083693A1 (en) 2000-05-22 2005-11-30 Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US11/408,026 US20060257324A1 (en) 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/289,479 Continuation-In-Part US20060083693A1 (en) 2000-05-22 2005-11-30 Stable pharmaceutical solution formulations for pressurised metered dose inhalers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/003420 Continuation WO2007121913A2 (en) 2006-04-21 2007-04-19 Pharmaceutical solution formulations for pressurised metered dose inhalers

Publications (1)

Publication Number Publication Date
US20060257324A1 true US20060257324A1 (en) 2006-11-16

Family

ID=38230023

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/408,026 Abandoned US20060257324A1 (en) 2000-05-22 2006-04-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
US12/255,075 Abandoned US20090130026A1 (en) 2006-04-21 2008-10-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
US15/353,978 Active US10525006B2 (en) 2006-04-21 2016-11-17 Pharmaceutical solution formulations for pressurised metered dose inhalers
US16/689,611 Active 2026-07-14 US11213485B2 (en) 2006-04-21 2019-11-20 Pharmaceutical solution formulations for pressurized metered dose inhalers

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/255,075 Abandoned US20090130026A1 (en) 2006-04-21 2008-10-21 Pharmaceutical solution formulations for pressurised metered dose inhalers
US15/353,978 Active US10525006B2 (en) 2006-04-21 2016-11-17 Pharmaceutical solution formulations for pressurised metered dose inhalers
US16/689,611 Active 2026-07-14 US11213485B2 (en) 2006-04-21 2019-11-20 Pharmaceutical solution formulations for pressurized metered dose inhalers

Country Status (21)

Country Link
US (4) US20060257324A1 (en)
EP (1) EP2010190B1 (en)
JP (1) JP5289306B2 (en)
KR (1) KR101311662B1 (en)
CN (4) CN101389341A (en)
AU (1) AU2007241336C1 (en)
BR (1) BRPI0709510A2 (en)
CA (1) CA2649556C (en)
CY (1) CY1114215T1 (en)
DK (1) DK2010190T3 (en)
EA (1) EA016262B1 (en)
ES (1) ES2424753T3 (en)
HR (1) HRP20130835T1 (en)
ME (1) ME02342B (en)
MX (1) MX2008013460A (en)
PL (1) PL2010190T3 (en)
PT (1) PT2010190E (en)
RS (1) RS52940B (en)
SI (1) SI2010190T1 (en)
WO (1) WO2007121913A2 (en)
ZA (1) ZA200808965B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033201A1 (en) * 1999-06-18 2004-02-19 3M Innovative Properties Company Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US20070086953A1 (en) * 2004-05-13 2007-04-19 Brian Meakin Medicinal Aerosol Formulation Products With Improved Chemical Stability
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2007121913A3 (en) * 2006-04-21 2008-03-06 Chiesi Farma Spa Pharmaceutical solution formulations for pressurised metered dose inhalers
US20080319006A1 (en) * 2005-01-31 2008-12-25 Breath Limited , A Corporation Nebulizer Formulation
US20100183725A1 (en) * 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
WO2010138158A1 (en) * 2009-05-15 2010-12-02 Map Pharmaceuticals, Inc. Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
WO2011045432A1 (en) * 2009-10-16 2011-04-21 Jagotec Ag Improved medicinal aerosol formulations
WO2011045429A1 (en) * 2009-10-16 2011-04-21 Jagotec Ag Improved formulations
US20110135737A1 (en) * 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
WO2011076841A3 (en) * 2009-12-23 2011-11-24 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2011076840A3 (en) * 2009-12-23 2011-12-01 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
WO2011076842A3 (en) * 2009-12-23 2011-12-01 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
WO2011076843A3 (en) * 2009-12-23 2011-12-01 Chiesi Farmaceutici S.P.A. Combination therapy for copd
EP2440196A1 (en) * 2009-06-09 2012-04-18 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
EP2536412B1 (en) * 2010-02-16 2014-11-12 Teva Branded Pharmaceutical Products R & D, Inc. An inhalable pharmaceutical composition
WO2015101576A1 (en) 2013-12-30 2015-07-09 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
RU2568882C2 (en) * 2010-07-16 2015-11-20 Сипла Лимитед Pharmaceutical compositions
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2017033032A1 (en) * 2015-08-27 2017-03-02 Jagotec Ag Pharmaceutical composition for inhalation
US9895327B2 (en) 2003-10-09 2018-02-20 Jagotec Ag Aerosol formulations comprising formoterol fumarate dihydrate
WO2021110239A1 (en) 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102266560A (en) * 2010-06-04 2011-12-07 北京阜康仁生物制药科技有限公司 Drug composition for treating asthma
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2017093758A1 (en) 2015-12-04 2017-06-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
AU2017328907B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CN115252552A (en) * 2016-09-19 2022-11-01 墨西哥氟石股份公司 Pharmaceutical composition
EP3515425B1 (en) 2016-09-19 2021-06-09 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising salmeterol
ES2891579T3 (en) 2016-09-19 2022-01-28 Mexichem Fluor Sa De Cv Pharmaceutical composition
AU2017328908B2 (en) 2016-09-19 2020-04-02 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
US20210315842A1 (en) 2018-06-04 2021-10-14 Lupin Inc. Stable pharmaceutical compositions for pressurized metered dose inhalers
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
CN111467498A (en) * 2020-05-14 2020-07-31 王兆霖 Pharmaceutical composition preparation
WO2022073009A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972919A (en) * 1991-12-18 1999-10-26 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
US6173047B1 (en) * 1997-08-11 2001-01-09 Dale W. Malik System and method for temporary voicemail service
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US20030066525A1 (en) * 1998-11-25 2003-04-10 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US6585958B1 (en) * 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US6716414B2 (en) * 2000-05-22 2004-04-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20040184993A1 (en) * 1998-11-25 2004-09-23 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050152846A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US6964759B2 (en) * 2000-02-22 2005-11-15 Chiesi Farmaceutici S.P.A. Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079210T3 (en) 1991-12-12 1996-01-01 Glaxo Group Ltd PHARMACEUTICAL FORMULATION OF AEROSOL.
US5483953A (en) * 1995-04-08 1996-01-16 The United States Of America As Represented By The Secretary Of The Navy Aerosol dispensing apparatus for dispensing a medicated vapor into the lungs of a patient
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
SE9900833D0 (en) 1999-03-09 1999-03-09 Astra Ab Novel combination
JP2003518484A (en) 1999-12-24 2003-06-10 グラクソ グループ リミテッド Pharmaceutical aerosol formulations of salmeterol and fluticasone propionate
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US6451287B1 (en) * 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
FI20002216A0 (en) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Combination particles for asthma therapy
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
US20030178022A1 (en) 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
EP2319582A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising formoterol, budesonide and tiotropium or oxitropium
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
CA2534985A1 (en) * 2003-08-11 2005-02-24 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
US20050287077A1 (en) * 2004-02-10 2005-12-29 James E. Shipley Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7914771B2 (en) 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US9808423B2 (en) * 2004-10-12 2017-11-07 Generics [Uk] Limited Preparation of suspension aerosol formulations
BRPI0608087A2 (en) * 2005-02-15 2009-11-10 Elan Pharma Int Ltd injectable and aerosol formulations of nanoparticulate benzodiazepine
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972919A (en) * 1991-12-18 1999-10-26 Astra Aktiebolag Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
US6461591B1 (en) * 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US20030190287A1 (en) * 1997-06-13 2003-10-09 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20040062720A1 (en) * 1997-06-13 2004-04-01 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US20030206870A1 (en) * 1997-06-13 2003-11-06 Chiesi Farmaceutici S.P.A. Pharaceutical aerosol composition
US6173047B1 (en) * 1997-08-11 2001-01-09 Dale W. Malik System and method for temporary voicemail service
US6585958B1 (en) * 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US20030066525A1 (en) * 1998-11-25 2003-04-10 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20030089369A1 (en) * 1998-11-25 2003-05-15 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20040096399A1 (en) * 1998-11-25 2004-05-20 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US20040184993A1 (en) * 1998-11-25 2004-09-23 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
US20050142071A1 (en) * 1998-11-25 2005-06-30 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers (MDI)
US6964759B2 (en) * 2000-02-22 2005-11-15 Chiesi Farmaceutici S.P.A. Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease
US20030190289A1 (en) * 2000-05-12 2003-10-09 David Lewis Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US6716414B2 (en) * 2000-05-22 2004-04-06 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7018618B2 (en) * 2000-05-22 2006-03-28 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US20060083693A1 (en) * 2000-05-22 2006-04-20 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20050129621A1 (en) * 2002-03-01 2005-06-16 Chiesi Farmaceutici S.P.A. Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
US20050152846A1 (en) * 2002-03-01 2005-07-14 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
US20060120966A1 (en) * 2002-10-23 2006-06-08 Chiesi Farmaceutici S.P.A. Salmeterol superfine formulation

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220717A1 (en) * 1999-06-18 2005-10-06 3M Innovative Properties Company Steroid solution aerosol products with enhanced chemical stability
US20040033201A1 (en) * 1999-06-18 2004-02-19 3M Innovative Properties Company Process for making chemically stable C-17/21 OH 20-ketosteroid aerosol products
US20040101483A1 (en) * 2001-03-30 2004-05-27 Rudi Muller-Walz Medical aerosol formulations
US9895327B2 (en) 2003-10-09 2018-02-20 Jagotec Ag Aerosol formulations comprising formoterol fumarate dihydrate
US20070086953A1 (en) * 2004-05-13 2007-04-19 Brian Meakin Medicinal Aerosol Formulation Products With Improved Chemical Stability
US20080319006A1 (en) * 2005-01-31 2008-12-25 Breath Limited , A Corporation Nebulizer Formulation
US20100183725A1 (en) * 2005-07-15 2010-07-22 Map Pharmaceuticals, Inc. Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
WO2007121913A3 (en) * 2006-04-21 2008-03-06 Chiesi Farma Spa Pharmaceutical solution formulations for pressurised metered dose inhalers
EA016262B1 (en) * 2006-04-21 2012-03-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Pharmaceutical solution formulations for pressurized metered dose inhalers
WO2008025787A3 (en) * 2006-08-31 2008-08-21 Novartis Ag Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US20100166671A1 (en) * 2006-08-31 2010-07-01 Collingwood Stephen P Organic compounds
WO2008025787A2 (en) * 2006-08-31 2008-03-06 Novartis Ag Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
WO2010138158A1 (en) * 2009-05-15 2010-12-02 Map Pharmaceuticals, Inc. Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
US20110135737A1 (en) * 2009-05-29 2011-06-09 Pearl Therapeutics, Inc. Compositions for respiratory delivery of active agents and associated methods and systems
US10716753B2 (en) 2009-05-29 2020-07-21 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
US9415009B2 (en) 2009-05-29 2016-08-16 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
EP2440196A1 (en) * 2009-06-09 2012-04-18 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
EP3811928A1 (en) * 2009-10-16 2021-04-28 Jagotec AG Improved formulations
WO2011045432A1 (en) * 2009-10-16 2011-04-21 Jagotec Ag Improved medicinal aerosol formulations
US10471077B2 (en) 2009-10-16 2019-11-12 Jagotec Ag Medicinal aerosol formulations
WO2011045429A1 (en) * 2009-10-16 2011-04-21 Jagotec Ag Improved formulations
EP4327807A3 (en) * 2009-10-16 2024-04-24 Jagotec AG Improved medicinal aerosol formulations
AU2010305695B2 (en) * 2009-10-16 2014-07-10 Jagotec Ag Improved formulations
JP2013515695A (en) * 2009-12-23 2013-05-09 シエシー ファルマセウティチィ ソシエタ ペル アチオニ Aerosol formulation for COPD
US11590074B2 (en) 2009-12-23 2023-02-28 Chiesi Farmaceutici S.P.A. Aerosol formulation for COPD
EA021604B1 (en) * 2009-12-23 2015-07-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Aerosol formulation for treating asthma and copd
EA021917B1 (en) * 2009-12-23 2015-09-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Combination therapy for asthma and copd
US10806701B2 (en) 2009-12-23 2020-10-20 Chiesi Farmaceutici S.P.A. Aerosol formulation for COPD
WO2011076841A3 (en) * 2009-12-23 2011-11-24 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2011076843A3 (en) * 2009-12-23 2011-12-01 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2011076840A3 (en) * 2009-12-23 2011-12-01 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
KR101747474B1 (en) 2009-12-23 2017-06-14 키에시 파르마슈티시 엣스. 피. 에이. Aerosol formulation for copd
KR101795348B1 (en) * 2009-12-23 2017-12-01 키에시 파르마슈티시 엣스. 피. 에이. Aerosol formulation for copd
AU2016234895B2 (en) * 2009-12-23 2018-02-01 Chiesi Farmaceutici S.P.A. Combination Therapy for COPD
WO2011076842A3 (en) * 2009-12-23 2011-12-01 Chiesi Farmaceutici S.P.A. Aerosol formulation for copd
AU2016234894B2 (en) * 2009-12-23 2018-02-22 Chiesi Farmaceutici S.P.A Aerosol Formulation for COPD
US11389401B2 (en) 2009-12-23 2022-07-19 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
US10159645B2 (en) 2009-12-23 2018-12-25 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
EP2536412B1 (en) * 2010-02-16 2014-11-12 Teva Branded Pharmaceutical Products R & D, Inc. An inhalable pharmaceutical composition
WO2011136754A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
WO2011136752A1 (en) * 2010-04-26 2011-11-03 Mahmut Bilgic Combined pharmaceutical composition comprising carmoterol and ciclesonide for the treatment of respiratory diseases
RU2568882C2 (en) * 2010-07-16 2015-11-20 Сипла Лимитед Pharmaceutical compositions
US11471468B2 (en) 2013-03-15 2022-10-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
EP3384898A1 (en) 2013-12-30 2018-10-10 Chiesi Farmaceutici S.p.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
EP3566694A1 (en) 2013-12-30 2019-11-13 Chiesi Farmaceutici S.p.a. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
WO2015101576A1 (en) 2013-12-30 2015-07-09 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
WO2017033032A1 (en) * 2015-08-27 2017-03-02 Jagotec Ag Pharmaceutical composition for inhalation
WO2021110239A1 (en) 2019-12-02 2021-06-10 Chiesi Farmaceutici S.P.A. Stainles steel can for pressurised metered dose inhalers

Also Published As

Publication number Publication date
JP5289306B2 (en) 2013-09-11
CA2649556A1 (en) 2007-11-01
ME02342B (en) 2016-06-20
AU2007241336A1 (en) 2007-11-01
EA200802012A1 (en) 2009-04-28
AU2007241336C1 (en) 2023-06-29
EA016262B1 (en) 2012-03-30
BRPI0709510A2 (en) 2011-07-19
CN102908308A (en) 2013-02-06
US20170065518A1 (en) 2017-03-09
US11213485B2 (en) 2022-01-04
WO2007121913A3 (en) 2008-03-06
SI2010190T1 (en) 2013-10-30
WO2007121913A2 (en) 2007-11-01
US10525006B2 (en) 2020-01-07
CA2649556C (en) 2014-04-15
CY1114215T1 (en) 2016-08-31
HRP20130835T1 (en) 2013-10-25
ES2424753T3 (en) 2013-10-08
RS52940B (en) 2014-02-28
DK2010190T3 (en) 2013-08-26
PL2010190T3 (en) 2013-11-29
AU2007241336B2 (en) 2012-12-06
CN105963249A (en) 2016-09-28
EP2010190A2 (en) 2009-01-07
CN101389341A (en) 2009-03-18
EP2010190B1 (en) 2013-06-12
MX2008013460A (en) 2008-10-29
PT2010190E (en) 2013-08-26
JP2009534333A (en) 2009-09-24
CN106074359A (en) 2016-11-09
US20090130026A1 (en) 2009-05-21
KR101311662B1 (en) 2013-09-25
US20200085729A1 (en) 2020-03-19
ZA200808965B (en) 2009-12-30
KR20080110985A (en) 2008-12-22

Similar Documents

Publication Publication Date Title
US20060257324A1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
US6716414B2 (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7381402B2 (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1480616B1 (en) Aerosol formulations of diisobutyryl apomorphine
TWI449523B (en) Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
US20070025920A1 (en) Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers
KR20060136446A (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers
MXPA06009584A (en) Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHIESI FARMACEUTICI S.P.A., ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEWIS, DAVID ANDREW;MEAKIN, BRIAN JOHN;BRAMBILLA, GAETANO;REEL/FRAME:018106/0939

Effective date: 20060608

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION